Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting

Video

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

Week 1 of the Virtual American Association for Cancer Research (AACR) 2021 Annual Meeting offered a variety of data on trials ranging from preclinical to phase 3 studies. In particular, Matthew J. Matasar, MD, is excited most about the presentations surrounding chromosomal instability in cancer.

Matasar, associate member of Lymphoma Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center, spoke with CancerNetwork® about his hopes for future treatments coming out of the meeting.

Transcription:

I think AACR, for me, really brings home the breadth of scientific investigation that’ s being applied to such patients and their illnesses. And I really see the future landscape of this set of illnesses as being one in which we’re going to have more effective and less toxic treatments for our patients.

[There’s] just a tremendous breadth of scientific inquiry that’s been presented this year. I’ve been particularly interested in the story of the chromosomal instability and found the work that was presented, looking at that and documenting how this works and the clinical implications of this is really being very provocative.

Reference:

Matasar MJ, Capra M, Ozcan M, et al. CHRONOS-3: randomized phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL). Presented at: 2021 AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract CT001.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content